| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Scientific Officer | EVP, Chief Scientific Officer
1 company
Joseph Y Chang last filed a Form 4 in March 2023, as Chief Scientific Officer at NUS. Joseph Y Chang's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Joseph Y Chang a strong insider score of 72/100, based on 6 past trades. Over a 12-month horizon, all 6 of those trades were profitable, with an average 12-month return of +33.6%.
At the last filing, the largest reported position was 21,234 shares of NUS. The NUS filings lean toward selling, a net 300,106 shares.
Joseph Y Chang has 39 Form 4 filings on record from March 2015 to March 2023, all as Chief Scientific Officer at Nu Skin Enterprises (NUS), 2015–2023.
The 85 reported transactions were 24 option exercises, 21 open-market sales, 18 tax withholdings and 13 option or other derivative awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 13 sales worth about $14.5M.
The largest open-market sale was 93,485 shares of NUS at an average $40.53 on March 2, 2023, about $3.8M. Twelve months later NUS was down 69%.
Shares as reported in the last Form 4 for each company; the most recent is from March 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 2, 2023 | NUS Nu Skin Enterprises, Inc. | Chief Scientific Officer | Sale+OE | 93,485 | $40.53 | $3,788,783.40 | -81.5% | -19.0% | -69.3% | |
| Jun 1, 2022 | NUS Nu Skin Enterprises, Inc. | Chief Scientific Officer | Sale+OE | 16,000 | $46.57 | $745,058.00 | -41.1% | -9.6% | -26.8% | |
| Mar 2, 2022 | NUS Nu Skin Enterprises, Inc. | Chief Scientific Officer | Sale+OE | 3,423 | $46.04 | $157,597.19 | -13.0% | -3.9% | -13.6% | |
| Mar 1, 2022 | NUS Nu Skin Enterprises, Inc. | Chief Scientific Officer | Sale+OE | 28,577 | $45.22 | $1,292,212.68 | -55.5% | +4.1% | -7.5% | |
| Sep 13, 2021 | NUS Nu Skin Enterprises, Inc. | EVP, Chief Scientific Officer | Sale+OE | 16,000 | $47.41 | $758,560.00 | -47.1% | +0.1% | -15.4% | |
| Mar 9, 2021 | NUS Nu Skin Enterprises, Inc. | Chief Scientific Officer | Sell | 626 | $51.55 | $32,270.30 | -3.4% | - | - | |
| Feb 18, 2021 | NUS Nu Skin Enterprises, Inc. | Chief Scientific Officer | Sell | 1,125 | $49.77 | $55,991.25 | -5.6% | - | - | |
| Sep 10, 2020 | NUS Nu Skin Enterprises, Inc. | Chief Scientific Officer | Sale+OE | 16,800 | $50.31 | $845,178.32 | -53.1% | - | - | |
| Jun 5, 2020 | NUS Nu Skin Enterprises, Inc. | Chief Scientific Officer | Sell | 34,970 | $40.01 | $1,399,149.70 | -48.0% | - | - | |
| Aug 9, 2018 | NUS Nu Skin Enterprises, Inc. | Chief Scientific Officer | Sale+OE | 10,600 | $82.13 | $870,612.00 | -15.1% | - | - |